Page last updated: 2024-10-23

aspirin and Elevated Cholesterol

aspirin has been researched along with Elevated Cholesterol in 143 studies

Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.

Research Excerpts

ExcerptRelevanceReference
"This study evaluated the efficacy of combined therapy with probucol and cilostazol on endothelial function in silent lacunar cerebral infarcts (SLCI) and mild hypercholesterolemia."9.19Combined therapeutic effect of probucol and cilostazol on endothelial function in patients with silent cerebral lacunar infarcts and hypercholesterolemia: a preliminary study. ( Hattori, H; Ishihara, M; Nagata, M; Takase, B; Tanaka, Y, 2014)
"In a laboratory substudy of the PRAGUE-8 trial, the influences of nonmodifiable (age and sex) and modifiable (body mass index and tobacco smoke) factors, comorbidity (hypertension, hyperlipidemia, diabetes mellitus, and renal insufficiency) and cotherapy (statin, aspirin, and heparin), on the course of clopidogrel efficacy were investigated in 105 patients pretreated with clopidogrel >or=6 hours before coronary angiography +/- percutaneous coronary intervention."9.14Factors influencing clopidogrel efficacy in patients with stable coronary artery disease undergoing elective percutaneous coronary intervention: statin's advantage and the smoking "paradox". ( Bilkova, D; Kala, P; Marinov, I; Motovska, Z; Petr, R; Simek, S; Widimsky, P, 2009)
"Fifty patients with hypercholesterolemia were randomly allocated to receive an 8-week therapeutic course of simvastatin 20 mg daily (n=25) or aspirin 100 mg daily (n=25)."9.10Enhanced interleukin-1beta in hypercholesterolemia: effects of simvastatin and low-dose aspirin. ( Basili, S; Cardarello, CM; Davi, G; Ferroni, P; Gazzaniga, PP; Martini, F, 2003)
"In men with hypercholesterolemia, lowering serum cholesterol level by a three-month simvastatin treatment is accompanied by a marked reduction of thrombin generation both at basal conditions in venous blood and after activation of hemostasis by microvascular injury."9.09Inhibition of thrombin generation by simvastatin and lack of additive effects of aspirin in patients with marked hypercholesterolemia. ( Gajewski, P; Góra, P; Jankowski, M; Musiał, J; Swadźba, J; Szczeklik, A; Undas, A, 1999)
"To evaluate the association between CDS tools and racial and sex disparities in the aspirin use, blood pressure control, cholesterol management, and smoking cessation (ABCS) care quality metrics among smaller primary care practices."8.31Differences in Use of Clinical Decision Support Tools and Implementation of Aspirin, Blood Pressure Control, Cholesterol Management, and Smoking Cessation Quality Metrics in Small Practices by Race and Sex. ( Atem, FD; Balasubramanian, BA; Marino, M; Roberts, MM; Wells, R, 2023)
"Beside its therapeutic role in the thrombotic vascular events, Clopidogrel confers significant protection against ischemic myocardial injury by counteracting the platelet-mediated inflammation and oxidative stress associated with HFD-C consumption in animals."7.96Clopidogrel Prophylaxis Abates Myocardial Ischemic Injury and Inhibits the Hyperlipidemia-Inflammation Loop in Hypercholestrolemic Mice. ( Korish, AA, 2020)
"We used a single, integrated, microsimulation model to generate comparable results for 3 services recommended by the US Preventive Services Task Force: aspirin counseling for the primary prevention of CVD and colorectal cancer, screening and treatment for lipid disorders (usually high cholesterol), and screening and treatment for hypertension."7.85Health Benefits and Cost-Effectiveness of Asymptomatic Screening for Hypertension and High Cholesterol and Aspirin Counseling for Primary Prevention. ( Dehmer, SP; Flottemesch, TJ; LaFrance, AB; Maciosek, MV, 2017)
"The US Preventive Services Task Force recommends aspirin use for men aged 45 to 79, when the potential benefit of preventing myocardial infarctions outweighs the potential harm of gastrointestinal hemorrhage."7.81Aspirin Use for the Primary Prevention of Myocardial Infarction Among Men in North Carolina, 2013. ( Fleming, E; Perry, GS; Tchwenko, S, 2015)
" The other 32 rats were subjected to induction of hypercholesterolemia by high-fat diet for 3 weeks, followed by induction of AMI by subcutaneous injections of isoproterenol (85 mg/kg/day, for 2 days)."7.80Assessment of the prophylactic role of aspirin and/or clopidogrel on experimentally induced acute myocardial infarction in hypercholesterolemic rats. ( El-Hadidy, WF; Mannaa, HF; Mohamed, AR, 2014)
"Aspirin failure in ischemic stroke prevention may exceed functional resistance to aspirin and could be associated with a higher prevalence of lacunar stroke, comorbidities, and/or adverse interactions with other drugs."7.78Ischemic stroke in patients receiving aspirin. ( Ameriso, S; Ameriso, SF; Povedano, GP; Pujol Lereis, VA, 2012)
"Exploration of atherogenic diet-induced diabetes mellitus and the evaluation of antidiabetic potential of aspirin were carried out in this study."7.77The effect of aspirin on atherogenic diet-induced diabetes mellitus. ( Kumar, A; Parmar, HS; Sethi, A, 2011)
"A 58-year-old Caucasian male with a history of coronary heart disease and hypercholesterolemia, under treatment with acetyl-salicylate for 6 years and simvastatin for 2 months, presented to the Emergency Department of our hospital with epigastric pain and vomiting of 24-hour duration."7.73A case of acute pancreatitis possibly associated with combined salicylate and simvastatin treatment. ( Antonopoulos, S; Filioti, K; Giannoulis, G; Karamanolis, D; Kokkoris, S; Mikros, S; Protopsaltis, J, 2005)
"In men with hypercholesterolemia simvastatin treatment lowers serum levels of CRP and proinflammatory cytokines."7.71Anti-inflammatory effects of simvastatin in subjects with hypercholesterolemia. ( Gajewski, P; Jankowski, M; Musial, J; Sydor, W; Szczeklik, A; Undas, A, 2001)
"Aspirin resistance was defined as having a closure time (CT) of <186 s with Col/Epi cartridges despite regular aspirin therapy."6.74Effect of high dose statin therapy on platelet function; statins reduce aspirin-resistant platelet aggregation in patients with coronary heart disease. ( Nisanci, Y; Oflaz, H; Pamukcu, B; Tirnaksiz, E, 2009)
"The Healthy Hearts in the Heartland (H3) study is part of a nationwide effort, EvidenceNOW, seeking to better understand the ability of small primary care practices to improve "ABCS" clinical quality measures: appropriate Aspirin therapy, Blood pressure control, Cholesterol management, and Smoking cessation."5.27Design of healthy hearts in the heartland (H3): A practice-randomized, comparative effectiveness study. ( Brown, T; Chung, I; Ciolino, JD; Jackson, KL; Kho, AN; Liss, DT; Murakami, L; Persell, SD; Walunas, TL, 2018)
"This study evaluated the efficacy of combined therapy with probucol and cilostazol on endothelial function in silent lacunar cerebral infarcts (SLCI) and mild hypercholesterolemia."5.19Combined therapeutic effect of probucol and cilostazol on endothelial function in patients with silent cerebral lacunar infarcts and hypercholesterolemia: a preliminary study. ( Hattori, H; Ishihara, M; Nagata, M; Takase, B; Tanaka, Y, 2014)
"In a laboratory substudy of the PRAGUE-8 trial, the influences of nonmodifiable (age and sex) and modifiable (body mass index and tobacco smoke) factors, comorbidity (hypertension, hyperlipidemia, diabetes mellitus, and renal insufficiency) and cotherapy (statin, aspirin, and heparin), on the course of clopidogrel efficacy were investigated in 105 patients pretreated with clopidogrel >or=6 hours before coronary angiography +/- percutaneous coronary intervention."5.14Factors influencing clopidogrel efficacy in patients with stable coronary artery disease undergoing elective percutaneous coronary intervention: statin's advantage and the smoking "paradox". ( Bilkova, D; Kala, P; Marinov, I; Motovska, Z; Petr, R; Simek, S; Widimsky, P, 2009)
"The main objective of this study was to assess whether aspirin 100 mg QD can improve blood pressure (BP) control and endothelial function in subjects with arterial hypertension (AH) and hypercholesterolaemia."5.11Effects of low-dose aspirin on blood pressure and endothelial function of treated hypertensive hypercholesterolaemic subjects. ( London, D; Magen, E; Mishal, J; Priluk, R; Viskoper, JR; Yosefy, C, 2005)
"During a 1-year treatment period, simvastatin, 20 mg/d, produced a sustained reduction of approximately one quarter in low-density lipoprotein cholesterol levels, with no evidence of toxicity, and aspirin, 100 mg/d, did not substantially increase the risk for a major bleeding episode."5.11First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease. ( Altmann, P; Armitage, J; Baigent, C; Baxter, A; Cairns, HS; Collins, R; Foley, RN; Frighi, V; Kourellias, K; Landray, M; Leaper, C; Ratcliffe, PJ; Rogerson, M; Scoble, JE; Tomson, CR; Warwick, G; Wheeler, DC, 2005)
"Fifty patients with hypercholesterolemia were randomly allocated to receive an 8-week therapeutic course of simvastatin 20 mg daily (n=25) or aspirin 100 mg daily (n=25)."5.10Enhanced interleukin-1beta in hypercholesterolemia: effects of simvastatin and low-dose aspirin. ( Basili, S; Cardarello, CM; Davi, G; Ferroni, P; Gazzaniga, PP; Martini, F, 2003)
"In men with hypercholesterolemia, lowering serum cholesterol level by a three-month simvastatin treatment is accompanied by a marked reduction of thrombin generation both at basal conditions in venous blood and after activation of hemostasis by microvascular injury."5.09Inhibition of thrombin generation by simvastatin and lack of additive effects of aspirin in patients with marked hypercholesterolemia. ( Gajewski, P; Góra, P; Jankowski, M; Musiał, J; Swadźba, J; Szczeklik, A; Undas, A, 1999)
"0001) after adjustment for age, aspirin use, smoking, physical activity, body mass index, and history of angina, hypertension, and high cholesterol."5.09Alcohol consumption and risk of coronary heart disease by diabetes status. ( Ajani, UA; Buring, JE; Gaziano, JM; Hennekens, CH; Liu, S; Lotufo, PA; Manson, JE, 2000)
" We used the search terms metabolic syndrome, abdominal obesity, waist circumference, insulin resistance, cardiovascular disease, prediabetes, diabetes, treatment, prevention, aspirin, hypertension, cholesterol, atherogenic dyslipidemia, lifestyle therapy, diet, and exercise."4.84A practical "ABCDE" approach to the metabolic syndrome. ( Bansal, S; Blaha, MJ; Blumenthal, RS; Defilippis, AP; Golden, SH; Rouf, R, 2008)
", statins), and aspirin therapy for the primary prevention of coronary heart disease (CHD) in an elderly patient population (age >or=65 y)."4.82Primary prevention of coronary heart disease in the elderly. ( Dornbrook-Lavender, KA; Pieper, JA; Roth, MT, 2003)
"To evaluate the association between CDS tools and racial and sex disparities in the aspirin use, blood pressure control, cholesterol management, and smoking cessation (ABCS) care quality metrics among smaller primary care practices."4.31Differences in Use of Clinical Decision Support Tools and Implementation of Aspirin, Blood Pressure Control, Cholesterol Management, and Smoking Cessation Quality Metrics in Small Practices by Race and Sex. ( Atem, FD; Balasubramanian, BA; Marino, M; Roberts, MM; Wells, R, 2023)
"Beside its therapeutic role in the thrombotic vascular events, Clopidogrel confers significant protection against ischemic myocardial injury by counteracting the platelet-mediated inflammation and oxidative stress associated with HFD-C consumption in animals."3.96Clopidogrel Prophylaxis Abates Myocardial Ischemic Injury and Inhibits the Hyperlipidemia-Inflammation Loop in Hypercholestrolemic Mice. ( Korish, AA, 2020)
"We used a single, integrated, microsimulation model to generate comparable results for 3 services recommended by the US Preventive Services Task Force: aspirin counseling for the primary prevention of CVD and colorectal cancer, screening and treatment for lipid disorders (usually high cholesterol), and screening and treatment for hypertension."3.85Health Benefits and Cost-Effectiveness of Asymptomatic Screening for Hypertension and High Cholesterol and Aspirin Counseling for Primary Prevention. ( Dehmer, SP; Flottemesch, TJ; LaFrance, AB; Maciosek, MV, 2017)
" The use of low doses of aspirin inhibits platelet aggregation and inflammation and prevents cardiovascular mortality."3.83Study of oxidative and inflammatory parameters in LDLr-KO mice treated with a hypercholesterolemic diet: Comparison between the use of Campomanesia xanthocarpa and acetylsalicylic acid. ( Beutler, H; Brusco, I; de Almeida, AS; de Oliveira, SM; Duarte, MM; Duarte, T; Hirsch, GE; Klafke, JZ; Nascimento, S; Parisi, MM; Pereira, RL; Porto, FG; Rubin, FH; Schmidt, A; Trevisan, G; Viecili, PR, 2016)
"The US Preventive Services Task Force recommends aspirin use for men aged 45 to 79, when the potential benefit of preventing myocardial infarctions outweighs the potential harm of gastrointestinal hemorrhage."3.81Aspirin Use for the Primary Prevention of Myocardial Infarction Among Men in North Carolina, 2013. ( Fleming, E; Perry, GS; Tchwenko, S, 2015)
" The other 32 rats were subjected to induction of hypercholesterolemia by high-fat diet for 3 weeks, followed by induction of AMI by subcutaneous injections of isoproterenol (85 mg/kg/day, for 2 days)."3.80Assessment of the prophylactic role of aspirin and/or clopidogrel on experimentally induced acute myocardial infarction in hypercholesterolemic rats. ( El-Hadidy, WF; Mannaa, HF; Mohamed, AR, 2014)
"Aspirin failure in ischemic stroke prevention may exceed functional resistance to aspirin and could be associated with a higher prevalence of lacunar stroke, comorbidities, and/or adverse interactions with other drugs."3.78Ischemic stroke in patients receiving aspirin. ( Ameriso, S; Ameriso, SF; Povedano, GP; Pujol Lereis, VA, 2012)
"Exploration of atherogenic diet-induced diabetes mellitus and the evaluation of antidiabetic potential of aspirin were carried out in this study."3.77The effect of aspirin on atherogenic diet-induced diabetes mellitus. ( Kumar, A; Parmar, HS; Sethi, A, 2011)
"05) of stroke with hypertension and diabetes mellitus; of myocardial infarction with hypertension, hypercholesterolemia, obesity, and smoking; and of peptic ulcer disease with aspirin, NSAIDs, and potassium."3.74Validation studies of the health improvement network (THIN) database for pharmacoepidemiology research. ( Bilker, WB; Lewis, JD; Schinnar, R; Strom, BL; Wang, X, 2007)
"Atherosclerosis being considered as an inflammatory disorder, the present study was undertaken to investigate the effectiveness of anti-inflammatory drugs (ibuprofen, aspirin, and celecoxib) in hypercholesterolemia."3.74Antiatherosclerotic activity of ibuprofen, a non-selective COX inhibitor--an animal study. ( Dabhi, JK; Mehta, A; Solanki, JK, 2008)
"Aspirin is a common preventative therapy in patients at risk for cardiovascular diseases, yet little is known about how aspirin protects the vasculature in hypercholesterolemia."3.74Roles of platelet and endothelial cell COX-1 in hypercholesterolemia-induced microvascular dysfunction. ( Granger, DN; Specian, RD; Tailor, A; Wallace, JL; Wood, KC, 2007)
"A 58-year-old Caucasian male with a history of coronary heart disease and hypercholesterolemia, under treatment with acetyl-salicylate for 6 years and simvastatin for 2 months, presented to the Emergency Department of our hospital with epigastric pain and vomiting of 24-hour duration."3.73A case of acute pancreatitis possibly associated with combined salicylate and simvastatin treatment. ( Antonopoulos, S; Filioti, K; Giannoulis, G; Karamanolis, D; Kokkoris, S; Mikros, S; Protopsaltis, J, 2005)
"In men with hypercholesterolemia simvastatin treatment lowers serum levels of CRP and proinflammatory cytokines."3.71Anti-inflammatory effects of simvastatin in subjects with hypercholesterolemia. ( Gajewski, P; Jankowski, M; Musial, J; Sydor, W; Szczeklik, A; Undas, A, 2001)
"As platelet hyperactivity is important in atherosclerosis and smoking, we hypothesized higher levels of soluble platelet membrane glycoprotein V (gpV) in 95 patients with peripheral artery disease (PAD) and 92 with coronary artery disease (CAD) compared to 99 healthy controls, and examined the effects of aspirin and of smoking two cigarettes on soluble gpV and platelet function."3.71Increased platelet glycoprotein V levels in patients with coronary and peripheral atherosclerosis--the influence of aspirin and cigarette smoking. ( Blann, AD; Cazenave, JP; Galajda, P; Gurney, D; Lanza, F; Lip, GY; Moog, S, 2001)
"108 male rabbits, aged 6 months, with experimental hypercholesterolemia and experimental abdominal aortic lesioning received different regimen of antiatherosclerotic treatment; 36 of them were treated with isradipine, a dihydropyridine calcium antagonist (0."3.68Concomitant aspirin treatment abolishes the antiatherosclerotic effects of the calcium channel blocker isradipine mediated by PGI2. ( Angelberger, P; Gerakakis, A; Keiler, A; Lupattelli, G; Pirich, C; Sinzinger, H; Virgolini, I, 1992)
"Aspirin resistance was defined as having a closure time (CT) of <186 s with Col/Epi cartridges despite regular aspirin therapy."2.74Effect of high dose statin therapy on platelet function; statins reduce aspirin-resistant platelet aggregation in patients with coronary heart disease. ( Nisanci, Y; Oflaz, H; Pamukcu, B; Tirnaksiz, E, 2009)
"Several studies have shown that treatment of coronary heart disease (CHD) does not meet the goals set in recommendations."2.73Age and gender biases in secondary prevention of coronary heart disease in a Finnish university hospital setting. ( Kähönen, M; Kallio, J; Kööbi, T; Lehtimäki, T; Lehtinen, R; Michou, SM; Niemelä, K; Nieminen, T; Nikus, K; Turjanmaa, V; Viik, J, 2007)
"After short episodes of reactive hyperemia, FMD was abolished by local infusion of the nitric oxide synthesis inhibitor N:(G)monomethyl-L-arginine (5."2.70Heterogenous nature of flow-mediated dilatation in human conduit arteries in vivo: relevance to endothelial dysfunction in hypercholesterolemia. ( Cross, J; Deanfield, JE; Donald, AE; Kharbanda, RK; MacAllister, RJ; Mullen, MJ; Taylor, M; Vallance, P, 2001)
" Significant predictors of pharmacokinetic response included infusion dose and weight."2.70First experience with direct factor Xa inhibition in patients with stable coronary disease: a pharmacokinetic and pharmacodynamic evaluation. ( Armstrong, PW; Becker, RC; Bovill, EG; Dyke, CK; Dzavik, V; Gardner, LH; Gerstenblith, G; Harrington, RA; Hasselblad, V; Hochman, JS; Kleiman, NS; Kunitada, S; Lincoff, AM; Robertson, TL; Shimoto, Y; Zillman, LA, 2002)
"Aspirin has higher side effect risks and requires a longer time to achieve benefit."2.52Primary prevention: do the very elderly require a different approach? ( Schwartz, JB, 2015)
"The definitions of transient ischemic attack (TIA) and stroke have evolved with advancements in medical imaging."2.50Stroke: transient ischemic attack. ( Silver, B; Wulf Silver, R, 2014)
"Late-onset sporadic Alzheimer's disease is a heterogeneous disorder."2.42Convergence of atherosclerosis and Alzheimer's disease: inflammation, cholesterol, and misfolded proteins. ( Casserly, I; Topol, E, 2004)
"Stroke is a preventable tragedy for nearly 750,000 people each year."2.42Medical prevention of stroke, 2003. ( Kirshner, HS, 2003)
"Current recommendations for the treatment of hypercholesterolemia include drug therapy for persons at sufficiently elevated risk for coronary heart disease."2.39Lowering risk without lowering cholesterol: implications for national cholesterol policy. ( Avins, AL; Browner, WS, 1996)
"Aspirin was prescribed in 99."1.56Baseline clinical characteristics and patient profile of the TURKMI registry: Results of a nation-wide acute myocardial infarction registry in Turkey. ( Akboğa, M; Aktaş, I; Aladağ, N; Arın, CB; Asoğlu, R; Deveci, OS; Doğan, A; Dural, M; Erol, MK; Güneş, Y; Ince, O; Kayıkçıoğlu, M; Kılıçkap, M; Kurt, IH; Örnek, E; Özkan, E; Şen, T; Sinan, ÜY; Somuncu, MU; Tüner, H; Yenerçağ, M; Zeybey, U, 2020)
"Aspirin users were found to be at increased risk for major gastrointestinal bleeding."1.46Should This Patient Receive Aspirin?: Grand Rounds Discussion From Beth Israel Deaconess Medical Center. ( Burns, RB; Graham, K; Reynolds, EE; Sawhney, MS, 2017)
"adults have a heart attack or stroke, resulting in approximately 30 deaths every hour and, for nonfatal events, often leading to long-term disability."1.40Million hearts: prevalence of leading cardiovascular disease risk factors--United States, 2005-2012. ( George, MG; Gillespie, C; Jamal, A; Ritchey, MD; Wall, HK, 2014)
"Aspirin treatment also restored endothelial function and beta(2)-adrenoceptor activity."1.35Antioxidative action of aspirin on endothelial function in hypercholesterolaemic rats. ( Fahim, M; Shahid, M; Sharma, KK; Tauseef, M, 2008)
"7%), all at low dosage levels."1.35[Prescription patterns for antilipidemic drugs in a group of Colombian patients]. ( Machado, JE; Mesa, G; Moncada, JC, 2008)
"Aspirin treatment prevented the rise in blood pressure, heart rate and significantly improved baroreflex sensitivity in hypercholesterolemic rats."1.34Aspirin restores normal baroreflex function in hypercholesterolemic rats by its antioxidative action. ( Fahim, M; Sharma, KK; Tauseef, M, 2007)
"Overweight and obesity are well-established risk factors for cardiovascular disease and decline in kidney function in individuals with existing chronic kidney disease (CKD)."1.33Association between body mass index and CKD in apparently healthy men. ( Buring, JE; Gaziano, JM; Gelber, RP; Kausz, AT; Kurth, T; Levey, AS; Manson, JE, 2005)
"The progress of leukoaraiosis is greatly inhibited by long-term correction of platelet hyper-aggregability."1.33Progress of leukoaraiosis is inhibited by correction of platelet hyper-aggregability. ( Fujita, S; Fukushima, K; Kawaguchi, T; Uehara, T, 2005)
"However, the treatment of hypercholesterolemia should be improved."1.33[Recording of risk factors and preventive pharmaceutical therapy among ischemic heart disease patients in family practice during the years 1993-1998]. ( Alperin, M; Goldfracht, M; Hermoni, D, 2006)
"During follow-up 56 recurrences occurred, making a total of 110 episodes of vitreous haemorrhage in 79 eyes of 54 patients."1.32Does cardiovascular therapy affect the onset and recurrence of preretinal and vitreous haemorrhage in diabetic eye disease? ( Banerjee, S; Denniston, AK; Dodson, PM; Gibson, JM, 2004)
"Aspirin treatment reduced the development of atherosclerosis by approximately 47%."1.32Suppression of oxidative stress as a mechanism of reduction of hypercholesterolemic atherosclerosis by aspirin. ( Lee, P; Prasad, K, 2003)
"Unstable angina was defined as transient S-T segment changes without significant increases in CK and CK-MB."1.31Prior aspirin use in unstable angina patients with modified plasma inflammatory markers and endothelial nitric oxide synthase in neutrophils. ( de Andres, R; Farré, J; García-Méndez, A; Gómez, J; López-Farré, A; Mateos-Cáreres, PJ; Rico, L; Romero, J; Sánchez de Miguel, L, 2002)
"During restenosis, an impairment of nitric oxide (NO)-dependent pathways may occur."1.31Effects of nitric oxide-releasing aspirin versus aspirin on restenosis in hypercholesterolemic mice. ( Cirino, G; Condorelli, M; Del Soldato, P; Ignarro, LJ; Napoli, C; Pinto, A; Sica, V; Sorrentino, R, 2001)
"Appropriate treatment of hypercholesterolemia occurred in 96% of patients referred to a clinical pharmacy specialist, compared with 68% of those followed by primary care providers alone (p<0."1.31Optimizing drug therapy in patients with cardiovascular disease: the impact of pharmacist-managed pharmacotherapy clinics in a primary care setting. ( Beckey, NP; Geber, J; Korman, L; Parra, D, 2002)
"The aspirin dose was 40 mg/d."1.30Both dietary fish-oil supplementation and aspirin fail to inhibit atherosclerosis in long-term vein bypass grafts in moderately hypercholesterolemic nonhuman primates. ( Almassi, GH; Boerboom, LE; Olinger, GN; Skrinska, VA, 1997)
" Urinary 8-epi-PGF2 alpha was unchanged after 2-week dosing with aspirin and indobufen despite complete suppression of TX metabolite excretion."1.30In vivo formation of 8-Epi-prostaglandin F2 alpha is increased in hypercholesterolemia. ( Alessandrini, P; Bon, GB; Bucciarelli, T; Ciabattoni, G; Cipollone, F; Costantini, F; Davi, G; Mezzetti, A; Minotti, G; Patrono, C, 1997)
"Treatment with aspirin, beta blockers, and angiotensin converting enzyme inhibitors."1.30Secondary prevention in coronary heart disease: baseline survey of provision in general practice. ( Campbell, NC; Deans, HG; Rawles, JM; Ritchie, LD; Thain, J, 1998)
"Treatment with aspirin for 2 or 7 days had no effect on the constrictive responses at the injured site 1 month after injury or on those at the noninjured site at all times examined."1.29Inhibitory effects of aspirin on coronary hyperreactivity to autacoids after arterial balloon injury in miniature pigs. ( Ibayashi, S; Kuga, T; Ohara, Y; Shimokawa, H; Takeshita, A; Tomoike, H, 1995)
"The extent of carotid atherosclerosis was determined by real-time B-mode ultrasonography."1.29Risk factors for carotid atherosclerosis and platelet activation. ( Matsui, Y; Michishita, H; Shimizu, S; Sugita, M; Uyama, O, 1994)
"Patients with transient ischemic attacks (TIA) were previously shown to have high plasma values of thiobarbituric acid-reactive substances (TBA-RS)."1.28Blood lipid peroxides in TIA: relation to platelet function and metabolic profile. ( Alessandri, C; Balsano, F; Caliendo, C; Censi, C; Germani, M; Ghiselli, A; Servi, M; Violi, F, 1989)
" However, twice daily dosing with dazoxiben was effective."1.27Prolongation of platelet survival in hypercholesterolaemic rabbits by CGS 12970 (3-methyl-2-(3-pyridyl)-1 indoleoctanoic acid) and dazoxiben. ( Ambler, J; Butler, KD; Butler, PA; Shand, RA; Wallis, RB, 1987)

Research

Studies (143)

TimeframeStudies, this research(%)All Research%
pre-199011 (7.69)18.7374
1990's35 (24.48)18.2507
2000's66 (46.15)29.6817
2010's27 (18.88)24.3611
2020's4 (2.80)2.80

Authors

AuthorsStudies
Abbasi, J1
Roberts, MM1
Marino, M1
Wells, R1
Atem, FD1
Balasubramanian, BA1
Korish, AA1
Erol, MK1
Kayıkçıoğlu, M1
Kılıçkap, M1
Arın, CB1
Kurt, IH1
Aktaş, I1
Güneş, Y1
Özkan, E1
Şen, T1
Ince, O1
Örnek, E1
Asoğlu, R1
Aladağ, N1
Zeybey, U1
Sinan, ÜY1
Dural, M1
Tüner, H1
Doğan, A1
Yenerçağ, M1
Akboğa, M1
Deveci, OS1
Somuncu, MU1
Dehmer, SP1
Maciosek, MV1
LaFrance, AB1
Flottemesch, TJ1
Burns, RB1
Graham, K1
Sawhney, MS1
Reynolds, EE1
Shelley, D1
Blechter, B1
Siman, N1
Jiang, N1
Cleland, C1
Ogedegbe, G1
Williams, S1
Wu, W1
Rogers, E1
Berry, C1
Ciolino, JD1
Jackson, KL1
Liss, DT1
Brown, T1
Walunas, TL1
Murakami, L1
Chung, I1
Persell, SD1
Kho, AN1
Ma, L1
Waldmann, E1
Ooi, EMM1
Chan, DC1
Barrett, HPR1
Watts, GF1
Parhofer, KG1
Weitz, JI1
Fazio, S1
Li, L1
Wang, S1
Huang, H1
Cai, Y1
Xi, Y1
Bai, Y1
Ma, C1
De Kam, PJ1
Luo, WL1
Wenning, L1
Ratcliffe, L1
Sisk, CM1
Royalty, J1
Radziszewski, W1
Wagner, JA1
Lai, E1
Takase, B1
Nagata, M1
Hattori, H1
Tanaka, Y1
Ishihara, M1
Silver, B1
Wulf Silver, R1
Ritchey, MD1
Wall, HK1
Gillespie, C1
George, MG1
Jamal, A1
Mohamed, AR1
El-Hadidy, WF1
Mannaa, HF1
Schwartz, JB1
Jończyk-Skórka, K1
Śliwczyńska-Rodziewicz, D1
Jarmak, A1
Kowalski, J1
Shah, NS1
Huffman, MD1
Ning, H1
Lloyd-Jones, DM1
Nevadunsky, NS1
Van Arsdale, A1
Strickler, HD1
Spoozak, LA1
Moadel, A1
Kaur, G1
Girda, E1
Goldberg, GL1
Einstein, MH1
Tchwenko, S1
Fleming, E1
Perry, GS1
Klafke, JZ1
Pereira, RL1
Hirsch, GE1
Parisi, MM1
Porto, FG1
de Almeida, AS1
Rubin, FH1
Schmidt, A1
Beutler, H1
Nascimento, S1
Trevisan, G1
Brusco, I1
de Oliveira, SM1
Duarte, MM1
Duarte, T1
Viecili, PR1
Jomni, T1
Bellakhal, S1
Abouda, M1
Abdelaali, I1
Douggui, H1
Matsuo, K1
Cahoon, SS1
Yoshihara, K1
Shida, M1
Kakuda, M1
Adachi, S1
Moeini, A1
Machida, H1
Garcia-Sayre, J1
Ueda, Y1
Enomoto, T1
Mikami, M1
Roman, LD1
Sood, AK1
Sanchez, J1
Illnait, J1
Mas, R1
Mendoza, S1
Fernandez, L1
Mesa, M1
Vega, H1
Fernandez, J1
Reyes, P1
Ruiz, D1
Blaha, MJ1
Bansal, S1
Rouf, R1
Golden, SH1
Blumenthal, RS1
Defilippis, AP1
Tauseef, M2
Shahid, M1
Sharma, KK2
Fahim, M2
Dabhi, JK1
Solanki, JK1
Mehta, A1
Motovska, Z1
Widimsky, P1
Petr, R1
Bilkova, D1
Marinov, I1
Simek, S1
Kala, P1
Galesic, M1
Garcia-Retamero, R1
Gigerenzer, G1
Mora, S1
Rifai, N1
Buring, JE4
Ridker, PM2
Hatoum, IJ1
Nelson, JJ1
Cook, NR1
Hu, FB1
Rimm, EB1
Sethi, A1
Parmar, HS1
Kumar, A1
Luzak, B1
Boncler, M1
Rywaniak, J1
Wilk, R1
Stanczyk, L1
Czyz, M1
Rysz, J1
Watala, C1
Tchan, M1
Sillence, D1
Pujol Lereis, VA1
Ameriso, S1
Povedano, GP1
Ameriso, SF1
Yusuf, S1
Pais, P1
Sigamani, A1
Xavier, D1
Afzal, R1
Gao, P1
Teo, KK1
Napoli, C2
Ackah, E1
De Nigris, F1
Del Soldato, P2
D'Armiento, FP1
Crimi, E1
Condorelli, M2
Sessa, WC1
Szczeklik, A7
Musiał, J3
Undas, A6
Mateos-Cáreres, PJ1
García-Méndez, A1
Farré, J1
Sánchez de Miguel, L1
Gómez, J1
de Andres, R1
Rico, L1
Romero, J1
López-Farré, A1
Prasad, K1
Lee, P1
Kurth, T2
Kase, CS1
Berger, K1
Schaeffner, ES1
Gaziano, JM3
Vaur, L1
Danchin, N1
Hanania, G1
Cambou, JP1
Lablanche, JM1
Blanchard, D1
Clerson, P1
Gueret, P1
Kirshner, HS1
Ferroni, P1
Martini, F1
Cardarello, CM1
Gazzaniga, PP1
Davi, G4
Basili, S2
Dornbrook-Lavender, KA1
Pieper, JA1
Roth, MT1
Sacco, M1
Pellegrini, F1
Roncaglioni, MC1
Avanzini, F1
Tognoni, G1
Nicolucci, A1
Banerjee, S1
Denniston, AK1
Gibson, JM1
Dodson, PM1
Casserly, I1
Topol, E1
Lim, HS1
Blann, AD2
Lip, GY4
Kim, C1
Beckles, GL1
Critchley, J1
Liu, J1
Zhao, D1
Wei, W1
Capewell, S1
Hirsh, J1
Bhatt, DL1
Freestone, B1
Rothwell, P3
Sudlow, C3
Gohlke, H1
McLaurin, EY1
Holliday, SL1
Williams, P1
Brey, RL1
Baigent, C1
Landray, M1
Leaper, C1
Altmann, P1
Armitage, J1
Baxter, A1
Cairns, HS1
Collins, R1
Foley, RN1
Frighi, V1
Kourellias, K1
Ratcliffe, PJ1
Rogerson, M1
Scoble, JE1
Tomson, CR1
Warwick, G1
Wheeler, DC1
Antonopoulos, S1
Mikros, S1
Kokkoris, S1
Protopsaltis, J1
Filioti, K1
Karamanolis, D1
Giannoulis, G1
Schaerlig, E1
Magen, E1
Viskoper, JR1
Mishal, J1
Priluk, R1
London, D1
Yosefy, C1
Sanak, M1
Gelber, RP1
Kausz, AT1
Manson, JE3
Levey, AS1
Fujita, S1
Kawaguchi, T1
Uehara, T1
Fukushima, K1
Wepner, U1
Shimamoto, K1
Kawana, M1
Lip, GH1
Goldfracht, M1
Alperin, M2
Hermoni, D1
Soares, PR1
Hueb, WA1
Lemos, PA1
Lopes, N1
Martinez, EE1
Cesar, LA1
Oliveira, SA1
Ramires, JA1
Batić-Mujanović, O1
Zildzić, M1
Beganlić, A1
Khalifeh, MR1
Redett, RJ1
Ishii, A1
Viñuela, F1
Murayama, Y1
Yuki, I1
Nien, YL1
Yeh, DT1
Vinters, HV1
Lewis, JD1
Schinnar, R1
Bilker, WB1
Wang, X1
Strom, BL1
Blinc, A1
Poredos, P1
Moyad, MA1
Merrick, GS1
Jonas, JB1
Michou, SM1
Kähönen, M1
Lehtimäki, T1
Nikus, K1
Viik, J1
Niemelä, K1
Kallio, J1
Lehtinen, R1
Kööbi, T1
Turjanmaa, V1
Nieminen, T1
Tirnaksiz, E1
Pamukcu, B1
Oflaz, H1
Nisanci, Y1
Tailor, A1
Wood, KC1
Wallace, JL1
Specian, RD1
Granger, DN1
Korbut, RA1
Guzik, B1
Adamek-Guzik, T1
Korbut, R1
Machado, JE1
Moncada, JC1
Mesa, G1
Kornitzer, M1
Stamler, J1
Schoenberger, JA1
Mann, GV1
Weber, G1
Bianciardi, G1
Toti, P1
Bronner, LL1
Kanter, DS1
Kuga, T2
Ohara, Y2
Shimokawa, H1
Ibayashi, S1
Tomoike, H2
Takeshita, A2
Fitch, LL1
Buchwald, H1
Matts, JP1
Johnson, JW1
Campos, CT1
Long, JM1
Uyama, O1
Matsui, Y1
Shimizu, S1
Michishita, H1
Sugita, M1
Sandercock, PA1
Hata, H1
Hirakawa, Y1
Yudkin, JS1
Smith, MJ1
Allen, KG1
Norman, JF1
Harris, MA1
Miller, CW1
Musial, J2
Swadzba, J2
Gora, PF1
Piwowarska, W1
Duplaga, M1
Avins, AL1
Browner, WS1
Calvo, F1
Barrabés, JA1
García-Dorado, D1
Gresele, P1
Violi, F2
Catalano, M1
Giammarresi, C1
Volpato, R1
Nenci, GG1
Ciabattoni, G3
Patrono, C3
Laperche, T1
Laurian, C1
Roudaut, R1
Steg, PG1
Boerboom, LE1
Olinger, GN1
Almassi, GH1
Skrinska, VA1
Alessandrini, P1
Mezzetti, A1
Minotti, G1
Bucciarelli, T1
Costantini, F1
Cipollone, F1
Bon, GB1
Cushman, M1
Stampfer, MJ1
Tracy, RP1
Hennekens, CH2
Campbell, NC1
Thain, J1
Deans, HG1
Ritchie, LD1
Rawles, JM1
Noon, JP1
Walker, BR1
Hand, MF1
Webb, DJ1
Astrup, P1
Gyntelberg, F1
Gajewski, P2
Góra, P1
Jankowski, M2
Kearney, D1
Fitzgerald, D1
Pascual, J1
Thiru, K1
Gray, J1
Majeed, A1
Ristimäe, T1
Zilmer, M1
Zilmer, K1
Kairane, C1
Kullisaar, T1
Teesalu, R1
Ogawa, T1
Sugidachi, A1
Naganuma, H1
Asai, F1
Ajani, UA1
Lotufo, PA1
Liu, S1
Ghanam, K1
Lavagna, C1
Burgaud, JL1
Javellaud, J1
Ea-Kim, L1
Oudart, N1
Mullen, MJ1
Kharbanda, RK1
Cross, J1
Donald, AE1
Taylor, M1
Vallance, P1
Deanfield, JE1
MacAllister, RJ1
Sydor, W1
Cockcroft, JR1
Wilkinson, IB1
Yki-Järvinen, H1
Cirino, G1
Sorrentino, R1
Sica, V1
Pinto, A1
Ignarro, LJ1
Kalashnikova, LA1
Nasonov, EL1
Aleksandrova, EN1
Kosheleva, NM1
Reshetniak, TM1
Salozhin, KV1
Lanza, F1
Galajda, P1
Gurney, D1
Moog, S1
Cazenave, JP1
Piscione, F1
Barbato, E1
Galasso, G1
Chiariello, M1
Anderson, HV1
McNatt, J1
Clubb, FJ1
Herman, M1
Maffrand, JP1
DeClerck, F1
Ahn, C1
Buja, LM1
Willerson, JT1
Campia, U1
Choucair, WK1
Bryant, MB1
Quyyumi, AA1
Cardillo, C1
Panza, JA1
Dyke, CK1
Becker, RC1
Kleiman, NS1
Hochman, JS1
Bovill, EG1
Lincoff, AM1
Gerstenblith, G1
Dzavik, V1
Gardner, LH1
Hasselblad, V1
Zillman, LA1
Shimoto, Y1
Robertson, TL1
Kunitada, S1
Armstrong, PW1
Harrington, RA1
Geber, J1
Parra, D1
Beckey, NP1
Korman, L1
Faergeman, O1
Gormsen, J1
Meinertz, H1
Pirich, C1
Lupattelli, G1
Virgolini, I1
Keiler, A1
Gerakakis, A1
Angelberger, P1
Sinzinger, H1
Averna, M1
Catalano, I1
Barbagallo, C1
Ganci, A1
Notarbartolo, A1
Terres, W1
Hamm, CW1
Ruchelka, A1
Weilepp, A1
Kupper, W1
Gross, PL1
Rand, ML1
Barrow, DV1
Packham, MA2
Creager, MA1
Cooke, JP1
Mendelsohn, ME1
Gallagher, SJ1
Coleman, SM1
Loscalzo, J1
Dzau, VJ1
Winocour, PD1
Vickers, JD1
Kinlough-Rathbone, RL1
Mustard, JF1
Becker, G1
Taylor, D1
Sarris, GE1
Fann, JI1
Sokoloff, MH1
Smith, DL1
Loveday, M1
Kosek, JC1
Stephens, RJ1
Cooper, AD1
May, K1
Willis, AL1
Alessandri, C1
Ghiselli, A1
Germani, M1
Caliendo, C1
Censi, C1
Servi, M1
Balsano, F1
Aviram, M1
Winterstein, G1
Brook, JG1
Butler, KD1
Butler, PA1
Shand, RA1
Ambler, J1
Wallis, RB1
Monti, M1
Campanacci, D1

Clinical Trials (11)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Midwest Small Practice Care Transformation Research Alliance (MSPCTRA)[NCT02598284]226 participants (Actual)Interventional2016-01-31Completed
A Study to Evaluate the Effects of Laropiprant on the Antiplatelet Effects of Clopidogrel and Aspirin in Combination and to Evaluate Single Dose Pharmacokinetics of MK0524A in Subjects With Primary Hypercholesterolemia or Mixed Dyslipidemia[NCT01012219]Phase 136 participants (Actual)Interventional2009-11-30Completed
Women's Health Study of Low-dose Aspirin and Vitamin E in Apparently Healthy Women[NCT00000479]Phase 339,876 participants (Actual)Interventional1992-09-30Completed
Effectiveness of Polypill for Primary Prevention of Cardiovascular Disease (PolyPars): Study Design and Rationale for a Pragmatic Cluster Randomized Controlled Trial[NCT03459560]Phase 34,415 participants (Actual)Interventional2015-12-20Active, not recruiting
Study of Heart and Renal Protection (SHARP): The Effects of Lowering LDL-cholesterol With Simvastatin 20mg Plus Ezetimibe 10mg in Patients With Chronic Kidney Disease: a Randomized Placebo-controlled Trial[NCT00125593]Phase 49,438 participants (Actual)Interventional2003-06-30Completed
A Multi-center, Double-Blind Randomized, Cross-over, Active-control, Comparative Clinical Study to Evaluate the Administration Time-dependent Antihypertensive Effects of Low Dose Aspirin in Well-Controlled Hypertensive Patients (Phase IV)[NCT00386529]Phase 4191 participants (Actual)Interventional2006-09-30Completed
[NCT00000490]Phase 30 participants Interventional1973-06-30Completed
[NCT00005442]0 participants Observational1994-06-30Completed
THE OMEGA-SPM-DOSE and OMEGA-SPM-PAD: Specialized Pro-Resolving Mediators in Patients With Peripheral Artery Disease[NCT02719665]30 participants (Actual)Interventional2016-03-31Completed
Arterial Imaging of Inflammation and Resolution After Endovascular Surgery[NCT03590769]Phase 19 participants (Actual)Interventional2017-06-01Completed
Regulation of Nitric Oxide Bioavailability in Chronic Obstructive Pulmonary Disease: A Mechanistic Approach[NCT01398943]60 participants (Actual)Interventional2010-09-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Cutaneous Bleeding Time (BT)

"Cutaneous bleeding Time (BT) on Day 8 after daily administration of laropiprant with aspirin and clopidogrel for 7 days versus BT on Day 8 after daily administration of placebo with aspirin and clopidogrel for 7 days.~The model used included treatment, period and sequence as fixed effect variables and subjects as the random effect variable.~Period 3 was not analyzed as bleeding time was not an objective for this part of the study." (NCT01012219)
Timeframe: Day 8

InterventionSeconds (Least Squares Mean)
Clopidogrel + Aspirin +Laropiprant478
Clopidogrel + Aspirin389

Number of Participants With Cancer, Excluding Nonmelanoma Skin Cancer

(NCT00000479)
Timeframe: Average follow-up 10.1 years

,,,
Interventionparticipants (Number)
Total invasive cancerCancer death
Aspirin + Vitamin E716152
Aspirin Only722132
Both Placebos706143
Vitamin E Only721156

Number of Participants With Major Cardiovascular Events (a Combined Endpoint of Nonfatal Myocardial Infarction, Nonfatal Stroke, and Total Cardiovascular Death)

(NCT00000479)
Timeframe: Average follow-up 10.1 years

,,,
InterventionParticipants (Number)
Major cardiovascular eventStrokeMyocardial infarctionCardiovascular death
Aspirin + Vitamin E23210810254
Aspirin Only2451139666
Both Placebos2721339974
Vitamin E Only2501339452

Coronary or Non-coronary Revascularization Among All Patients Ever Randomized to Simvastatin Plus Ezetimibe Versus All Patients Allocated to Placebo

Revascularization included any arterial revascularization procedure, whether surgical or percutaneous, but excluded revascularization performed for hemodialysis vascular access (e.g. fistuloplasty) or to the donor kidney transplant artery. Revascularization included amputations for vascular disease (rather than for trauma or infection). All potential revascularization events (including angiography) were adjudicated, using pre-specified objective criteria, by clinicians blinded to study treatment allocation and lipid levels. Numbers provided = number of patients with events. (NCT00125593)
Timeframe: Median follow-up 4.9 years

Interventionparticipants (Number)
Simvastatin Plus Ezetimibe284
Placebo352

End-stage Renal Disease Among All Patients Not on Dialysis at the Time of Randomization to Simvastatin Plus Ezetimibe Versus Placebo

End-stage renal disease was defined as initiation of maintenance dialysis or renal transplantation. Temporary dialysis was excluded. All potential dialysis and transplant events were adjudicated, using pre-specified objective criteria, by clinicians blinded to study treatment allocation and lipid levels. Numbers provided = number of patients with events. (NCT00125593)
Timeframe: Median follow-up 4.9 years

Interventionparticipants (Number)
Simvastatin Plus Ezetimibe1057
Placebo1084

Key Outcome as Per Statistical Analysis Plan = Major Atherosclerotic Events Among All Patients Ever Randomized to Simvastatin Plus Ezetimibe Versus All Patients Allocated to Placebo

Major atherosclerotic events defined as non-fatal myocardial infarction or coronary death, non-hemorrhagic stroke, or any arterial revascularization procedure (excluding dialysis access procedures). Numbers provided = number of patients with events. (NCT00125593)
Timeframe: Median follow-up 4.9 years

Interventionparticipants (Number)
Simvastatin Plus Ezetimibe526
Placebo619

Major Coronary Events Among All Patients Ever Randomized to Simvastatin Plus Ezetimibe Versus All Patients Allocated to Placebo

Major coronary events defined as coronary death or non-fatal myocardial infarction. Myocardial infarction adjudicated based on the presence of serial changes in cardiac biomarkers (e.g. troponin, creatine kinase), typical ECG changes and typical cardiac symptoms. If myocardial infarction was fatal and post-mortem examination findings were available, this information was also assessed. All potential coronary events were adjudicated, using pre-specified objective criteria, by clinicians blinded to study treatment allocation and lipid levels. Numbers provided = number of patients with events. (NCT00125593)
Timeframe: Median follow-up 4.9 years

Interventionparticipants (Number)
Simvastatin Plus Ezetimibe213
Placebo230

Major Vascular Events Analyzed Among All Patients Ever Randomized to Simvastatin Plus Ezetimibe Versus All Patients Allocated to Placebo

Major vascular events defined as non-fatal myocardial infarction or cardiac death, any stroke, or any arterial revascularization procedure (excluding dialysis access procedures). Numbers provided = number of patients with events. (NCT00125593)
Timeframe: Median follow-up 4.9 years

Interventionparticipants (Number)
Simvastatin Plus Ezetimibe701
Placebo814

Major Vascular Events Analyzed Amongst Patients Initially Randomized to Simvastatin Plus Ezetimibe Versus Placebo (Original Protocol-defined Primary Outcome)

Major vascular events defined as non-fatal myocardial infarction or cardiac death, any stroke, or any arterial revascularization procedure (excluding dialysis access procedures). Numbers provided = number of patients with events. (NCT00125593)
Timeframe: Median follow-up 4.9 years

Interventionparticipants (Number)
Simvastatin Plus Ezetimibe639
Placebo749

Non-hemorrhagic Stroke Among All of Patients Ever Randomized to Simvastatin Plus Ezetimibe Versus All Patients Allocated to Placebo

Stroke was defined as rapid onset of focal or global neurological deficit, with duration greater than 24 hours. Clinical notes and brain imaging were sought to determine the stroke etiology, and if the stroke was fatal and post-mortem examination findings were available, this information was also assessed. All potential stroke events (including transient ischemic attack and intracerebral hemorrhage) were adjudicated, using pre-specified objective criteria, by clinicians blinded to study treatment allocation and lipid levels. Numbers provided = number of patients with events. (NCT00125593)
Timeframe: Median follow-up 4.9 years

Interventionparticipants (Number)
Simvastatin Plus Ezetimibe131
Placebo174

Flow-Mediated Dilation (FMD)

Brachial artery FMD induced by reactive hyperemia will be used to assess vascular endothelial function at baseline and several hours after each experimental intervention. (NCT01398943)
Timeframe: Post FMD was taken approximately 110 min after baseline

,
Interventionpercentage of change in FMD (Mean)
PlaceboAOC Treatment
All Controls6.76.9
All COPD Patients3.14.7

Pulse Wave Velocity

A measure of vascular stiffness at baseline and several hours after each experimental intervention. (NCT01398943)
Timeframe: Post PWV was taken approximately 90 min after baseline

,
Interventionm/sec (Mean)
PlaceboAOC Treatment
All Controls1110
All COPD Patients1411

Reviews

25 reviews available for aspirin and Elevated Cholesterol

ArticleYear
Stroke: transient ischemic attack.
    FP essentials, 2014, Volume: 420

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain; Clopidogrel; Diffusion Magnetic Resonance I

2014
Primary prevention: do the very elderly require a different approach?
    Trends in cardiovascular medicine, 2015, Volume: 25, Issue:3

    Topics: Aged, 80 and over; Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Dementia; Humans; Hydr

2015
A practical "ABCDE" approach to the metabolic syndrome.
    Mayo Clinic proceedings, 2008, Volume: 83, Issue:8

    Topics: Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Diet Therapy; Early Diagnosis; Evidence-Based M

2008
Medical prevention of stroke, 2003.
    Southern medical journal, 2003, Volume: 96, Issue:4

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Aspirin; Diet; Female; Humans; Hyp

2003
Primary prevention of coronary heart disease in the elderly.
    The Annals of pharmacotherapy, 2003, Volume: 37, Issue:11

    Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Aspirin; Coronary Disease; Humans; Hypercholestero

2003
Convergence of atherosclerosis and Alzheimer's disease: inflammation, cholesterol, and misfolded proteins.
    Lancet (London, England), 2004, Apr-03, Volume: 363, Issue:9415

    Topics: Aged; Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Arteriosclerosis; Aspirin; Cholest

2004
Comparative benefits of clopidogrel and aspirin in high-risk patient populations: lessons from the CAPRIE and CURE studies.
    Archives of internal medicine, 2004, Oct-25, Volume: 164, Issue:19

    Topics: Angina, Unstable; Aspirin; Clopidogrel; Comorbidity; Diabetes Mellitus; Humans; Hypercholesterolemia

2004
Stroke prevention.
    Clinical evidence, 2003, Issue:10

    Topics: Angioplasty, Balloon; Anticoagulants; Antihypertensive Agents; Aspirin; Atrial Fibrillation; Humans;

2003
[Primary prevention of cardiovascular disease].
    Deutsche medizinische Wochenschrift (1946), 2005, Jan-07, Volume: 130, Issue:1-2

    Topics: Adult; Age Factors; Aged; Antihypertensive Agents; Aspirin; Body Mass Index; Cardiovascular Diseases

2005
Stroke prevention.
    Clinical evidence, 2004, Issue:12

    Topics: Angioplasty, Balloon; Anticoagulants; Antihypertensive Agents; Aspirin; Atrial Fibrillation; Drug Th

2004
Aspirin resistance.
    Journal of thrombosis and haemostasis : JTH, 2005, Volume: 3, Issue:8

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Clinical Trials as Topic;

2005
[Acute coronary syndrome risk management].
    Nihon rinsho. Japanese journal of clinical medicine, 2006, Volume: 64, Issue:4

    Topics: Angina, Unstable; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Coronary Artery Disease; Humans

2006
Stroke prevention.
    Clinical evidence, 2005, Issue:14

    Topics: Angioplasty, Balloon; Anticoagulants; Antihypertensive Agents; Aspirin; Drug Therapy, Combination; E

2005
The management of patients on anticoagulants prior to cutaneous surgery: case report of a thromboembolic complication, review of the literature, and evidence-based recommendations.
    Plastic and reconstructive surgery, 2006, Volume: 118, Issue:5

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Damage,

2006
Pharmacological prevention of atherothrombotic events in patients with peripheral arterial disease.
    European journal of clinical investigation, 2007, Volume: 37, Issue:3

    Topics: Antihypertensive Agents; Aspirin; Cardiovascular Agents; Diabetic Angiopathies; Humans; Hydroxymethy

2007
Primary prevention of stroke.
    The New England journal of medicine, 1995, Nov-23, Volume: 333, Issue:21

    Topics: Aspirin; Cerebrovascular Disorders; Contraceptives, Oral; Diabetes Complications; Diet; Estrogen Rep

1995
How can we best prolong life? Benefits of coronary risk factor reduction in non-diabetic and diabetic subjects.
    BMJ (Clinical research ed.), 1993, May-15, Volume: 306, Issue:6888

    Topics: Adult; Aspirin; Blood Pressure; Coronary Disease; Diabetes Mellitus; England; Humans; Hypercholester

1993
Thrombin generation in myocardial infarction and hypercholesterolemia: effects of aspirin.
    Thrombosis and haemostasis, 1995, Volume: 74, Issue:1

    Topics: Aspirin; Death, Sudden, Cardiac; Depression, Chemical; Female; Fibrinolysis; Fibrinolytic Agents; Hu

1995
Lowering risk without lowering cholesterol: implications for national cholesterol policy.
    Annals of internal medicine, 1996, Sep-15, Volume: 125, Issue:6

    Topics: Adult; Antihypertensive Agents; Aspirin; Coronary Disease; Drug Costs; Estrogen Replacement Therapy;

1996
The anti-thrombotic effects of statins.
    Journal of the American College of Cardiology, 1999, Volume: 33, Issue:5

    Topics: Aspirin; Blood Coagulation Factors; Cholesterol, HDL; Cholesterol, LDL; Coronary Thrombosis; Humans;

1999
Heart disease in older patients.
    The Practitioner, 1998, Volume: 242, Issue:1589

    Topics: Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Aspirin;

1998
Stroke. Preemptive strikes.
    Harvard health letter, 2000, Volume: 25, Issue:6

    Topics: Alcohol Drinking; Aspirin; Female; Hormone Replacement Therapy; Humans; Hypercholesterolemia; Hypert

2000
Multiple risk factor intervention in type 2 diabetes: an opportunity not to be missed.
    Diabetes, obesity & metabolism, 2001, Volume: 3, Issue:1

    Topics: Aspirin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Endothelium, Vascular; Humans; Hypercho

2001
[Diabetes and ischemic cardiopathy].
    Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology, 2001, Volume: 2, Issue:9

    Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Coronary Disease; Diabetic Angiopathies; Hu

2001
[Primary prevention of intermittent claudication and frequently associated arteriopathies].
    Therapeutische Umschau. Revue therapeutique, 1987, Volume: 44, Issue:9

    Topics: Adult; Aspirin; Cerebrovascular Disorders; Coronary Disease; Diet; Humans; Hypercholesterolemia; Hyp

1987

Trials

27 trials available for aspirin and Elevated Cholesterol

ArticleYear
Quality of Cardiovascular Disease Care in Small Urban Practices.
    Annals of family medicine, 2018, Volume: 16, Issue:Suppl 1

    Topics: Aspirin; Cardiovascular Diseases; Cross-Sectional Studies; Delivery of Health Care; Guideline Adhere

2018
Design of healthy hearts in the heartland (H3): A practice-randomized, comparative effectiveness study.
    Contemporary clinical trials, 2018, Volume: 71

    Topics: Adult; Aspirin; Blood Pressure Determination; Cardiovascular Diseases; Female; Health Facility Size;

2018
Effects of Rosuvastatin and Aspirin on Retinal Vascular Structures in Hypercholesterolemic Patients with Low-to-Moderate Risk of Coronary Artery Disease.
    American journal of cardiovascular drugs : drugs, devices, and other interventions, 2019, Volume: 19, Issue:4

    Topics: Arterioles; Asian People; Aspirin; Atherosclerosis; C-Reactive Protein; Coronary Artery Disease; Fem

2019
The effects of laropiprant on the antiplatelet activity of co-administered clopidogrel and aspirin.
    Platelets, 2014, Volume: 25, Issue:7

    Topics: Adult; Aged; Aspirin; Clopidogrel; Cross-Over Studies; Double-Blind Method; Drug Interactions; Dysli

2014
Combined therapeutic effect of probucol and cilostazol on endothelial function in patients with silent cerebral lacunar infarcts and hypercholesterolemia: a preliminary study.
    Medical principles and practice : international journal of the Kuwait University, Health Science Centre, 2014, Volume: 23, Issue:1

    Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Agents; Cholinergic Antagonists; Cilostazol; Drug T

2014
[Long-term effect of policosanol on the functional recovery of non-cardioembolic ischemic stroke patients: a one year study].
    Revista de neurologia, 2017, Feb-16, Volume: 64, Issue:4

    Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Aspirin; Brain Damage, Chronic; Brain Ischemia; C

2017
Factors influencing clopidogrel efficacy in patients with stable coronary artery disease undergoing elective percutaneous coronary intervention: statin's advantage and the smoking "paradox".
    Journal of cardiovascular pharmacology, 2009, Volume: 53, Issue:5

    Topics: Age Factors; Aged; Angioplasty, Balloon, Coronary; Aspirin; Body Mass Index; Cell Adhesion Molecules

2009
The effect of a platelet cholesterol modulation on the acetylsalicylic acid-mediated blood platelet inhibition in hypercholesterolemic patients.
    European journal of pharmacology, 2011, May-11, Volume: 658, Issue:2-3

    Topics: Acetylation; Aspirin; Atorvastatin; Blood Platelets; Blood Proteins; Cholesterol; Drug Interactions;

2011
Comparison of risk factor reduction and tolerability of a full-dose polypill (with potassium) versus low-dose polypill (polycap) in individuals at high risk of cardiovascular diseases: the Second Indian Polycap Study (TIPS-2) investigators.
    Circulation. Cardiovascular quality and outcomes, 2012, Jul-01, Volume: 5, Issue:4

    Topics: Administration, Oral; Aged; Analysis of Variance; Antihypertensive Agents; Aspirin; Atenolol; Biomar

2012
Enhanced interleukin-1beta in hypercholesterolemia: effects of simvastatin and low-dose aspirin.
    Circulation, 2003, Oct-07, Volume: 108, Issue:14

    Topics: Adult; Aged; Aspirin; Female; Humans; Hypercholesterolemia; Interleukin-1; Male; Middle Aged; Platel

2003
Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial.
    Diabetes care, 2003, Volume: 26, Issue:12

    Topics: Aged; Aspirin; Blood Pressure; Body Mass Index; Cardiovascular Diseases; Diabetes Mellitus, Type 2;

2003
First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease.
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 2005, Volume: 45, Issue:3

    Topics: Adult; Aged; Alanine Transaminase; Aspirin; Cardiovascular Diseases; Cholesterol, LDL; Chronic Disea

2005
Effects of low-dose aspirin on blood pressure and endothelial function of treated hypertensive hypercholesterolaemic subjects.
    Journal of human hypertension, 2005, Volume: 19, Issue:9

    Topics: Adult; Antihypertensive Agents; Aspirin; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Brac

2005
Coronary revascularization (surgical or percutaneous) decreases mortality after the first year in diabetic subjects but not in nondiabetic subjects with multivessel disease: an analysis from the Medicine, Angioplasty, or Surgery Study (MASS II).
    Circulation, 2006, Jul-04, Volume: 114, Issue:1 Suppl

    Topics: Adrenergic beta-Antagonists; Aged; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assis

2006
Age and gender biases in secondary prevention of coronary heart disease in a Finnish university hospital setting.
    Clinical drug investigation, 2007, Volume: 27, Issue:10

    Topics: Adrenergic beta-Antagonists; Adult; Age Factors; Aged; Angiotensin-Converting Enzyme Inhibitors; Asp

2007
Effect of high dose statin therapy on platelet function; statins reduce aspirin-resistant platelet aggregation in patients with coronary heart disease.
    Journal of thrombosis and thrombolysis, 2009, Volume: 27, Issue:1

    Topics: Adenosine Diphosphate; Adult; Aged; Aspirin; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Colla

2009
Pharmacological trials: primary and secondary prevention of coronary heart disease.
    Preventive medicine, 1983, Volume: 12, Issue:1

    Topics: Aspirin; Cholestyramine Resin; Clinical Trials as Topic; Clofibrate; Colestipol; Coronary Disease; D

1983
Controversies in cardiology. Proposed: low-dose aspirin should be taken daily after age 40 if total serum cholesterol is greater than 160.
    Hospital practice (Office ed.), 1982, Volume: 17, Issue:12

    Topics: Adult; Aspirin; Blood Platelets; Clinical Trials as Topic; Coronary Disease; Epoprostenol; Humans; H

1982
Effect of aspirin use on death and recurrent myocardial infarction in current and former cigarette smokers. Program on the Surgical Control of the Hyperlipidemias Group.
    American heart journal, 1995, Volume: 129, Issue:4

    Topics: Aspirin; Cohort Studies; Coronary Artery Disease; Female; Follow-Up Studies; Humans; Hypercholestero

1995
Diabetes mellitus, hypercholesterolemia, and hypertension but not vascular disease per se are associated with persistent platelet activation in vivo. Evidence derived from the study of peripheral arterial disease.
    Circulation, 1997, Jul-01, Volume: 96, Issue:1

    Topics: Adult; Aged; Aspirin; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Female; Follow-Up Studies;

1997
Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease.
    Circulation, 1998, Feb-10, Volume: 97, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antioxidants; Arteriosclerosis; Aspirin; beta Carotene; Body Mass In

1998
Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease.
    Circulation, 1998, Feb-10, Volume: 97, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antioxidants; Arteriosclerosis; Aspirin; beta Carotene; Body Mass In

1998
Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease.
    Circulation, 1998, Feb-10, Volume: 97, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antioxidants; Arteriosclerosis; Aspirin; beta Carotene; Body Mass In

1998
Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease.
    Circulation, 1998, Feb-10, Volume: 97, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antioxidants; Arteriosclerosis; Aspirin; beta Carotene; Body Mass In

1998
Impairment of forearm vasodilatation to acetylcholine in hypercholesterolemia is reversed by aspirin.
    Cardiovascular research, 1998, Volume: 38, Issue:2

    Topics: Acetylcholine; Adult; Aspirin; Cyclooxygenase Inhibitors; Female; Forearm; Humans; Hypercholesterole

1998
Inhibition of thrombin generation by simvastatin and lack of additive effects of aspirin in patients with marked hypercholesterolemia.
    Journal of the American College of Cardiology, 1999, Volume: 33, Issue:5

    Topics: Adult; Aspirin; Biomarkers; Cholesterol; Drug Synergism; Drug Therapy, Combination; Fibrinopeptide A

1999
Alcohol consumption and risk of coronary heart disease by diabetes status.
    Circulation, 2000, Aug-01, Volume: 102, Issue:5

    Topics: Alcohol Drinking; Aspirin; beta Carotene; Cardiovascular Diseases; Coronary Disease; Diabetes Mellit

2000
Heterogenous nature of flow-mediated dilatation in human conduit arteries in vivo: relevance to endothelial dysfunction in hypercholesterolemia.
    Circulation research, 2001, Feb-02, Volume: 88, Issue:2

    Topics: Acetylcholine; Adolescent; Adult; Area Under Curve; Aspirin; Autonomic Agents; Blood Flow Velocity;

2001
Role of cyclooxygenase products in the regulation of vascular tone and in the endothelial vasodilator function of normal, hypertensive, and hypercholesterolemic humans.
    The American journal of cardiology, 2002, Feb-01, Volume: 89, Issue:3

    Topics: Acetylcholine; Aspirin; Blood Flow Velocity; Brachial Artery; Cholesterol; Cholesterol, HDL; Cholest

2002
First experience with direct factor Xa inhibition in patients with stable coronary disease: a pharmacokinetic and pharmacodynamic evaluation.
    Circulation, 2002, May-21, Volume: 105, Issue:20

    Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Anticoagulants; Aspirin

2002

Other Studies

91 other studies available for aspirin and Elevated Cholesterol

ArticleYear
Highlights From the American Heart Association's Scientific Sessions-ApoB as a Risk Marker, an Oral PCSK9 Inhibitor, and Aspirin and Dementia.
    JAMA, 2022, Jan-25, Volume: 327, Issue:4

    Topics: Administration, Oral; American Heart Association; Apolipoprotein B-100; Aspirin; Biomarkers; Dementi

2022
Differences in Use of Clinical Decision Support Tools and Implementation of Aspirin, Blood Pressure Control, Cholesterol Management, and Smoking Cessation Quality Metrics in Small Practices by Race and Sex.
    JAMA network open, 2023, 08-01, Volume: 6, Issue:8

    Topics: Aspirin; Benchmarking; Blood Pressure; Cardiovascular Diseases; Cholesterol; Cross-Sectional Studies

2023
Clopidogrel Prophylaxis Abates Myocardial Ischemic Injury and Inhibits the Hyperlipidemia-Inflammation Loop in Hypercholestrolemic Mice.
    Archives of medical research, 2020, Volume: 51, Issue:6

    Topics: Animals; Aspirin; Clopidogrel; Disease Models, Animal; Humans; Hypercholesterolemia; Hyperlipidemias

2020
Baseline clinical characteristics and patient profile of the TURKMI registry: Results of a nation-wide acute myocardial infarction registry in Turkey.
    Anatolian journal of cardiology, 2020, Volume: 24, Issue:1

    Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Angiotensin Receptor Antagonists; Angiotensin-Conver

2020
Health Benefits and Cost-Effectiveness of Asymptomatic Screening for Hypertension and High Cholesterol and Aspirin Counseling for Primary Prevention.
    Annals of family medicine, 2017, Volume: 15, Issue:1

    Topics: Adolescent; Adult; Aged; Aspirin; Colorectal Neoplasms; Cost-Benefit Analysis; Counseling; Ethnicity

2017
Should This Patient Receive Aspirin?: Grand Rounds Discussion From Beth Israel Deaconess Medical Center.
    Annals of internal medicine, 2017, 12-05, Volume: 167, Issue:11

    Topics: Anticholesteremic Agents; Aspirin; Cardiovascular Diseases; Gastrointestinal Hemorrhage; Humans; Hyp

2017
Lipoprotein (a) and Low-density lipoprotein apolipoprotein B metabolism following apheresis in patients with elevated lipoprotein(a) and coronary artery disease.
    European journal of clinical investigation, 2019, Volume: 49, Issue:2

    Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Apolipoproteins B; Aspirin; Blood Component Remov

2019
Overview of Therapeutic Approaches for Cholesterol Lowering and Attenuation of Thrombosis for Prevention of Atherothrombosis.
    Circulation research, 2019, Volume: 124, Issue:3

    Topics: Anticholesteremic Agents; Aspirin; Cholesterol, LDL; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Re

2019
Million hearts: prevalence of leading cardiovascular disease risk factors--United States, 2005-2012.
    MMWR. Morbidity and mortality weekly report, 2014, May-30, Volume: 63, Issue:21

    Topics: Adolescent; Adult; Aged; Aspirin; Cardiovascular Diseases; Female; Health Promotion; Humans; Hyperch

2014
Assessment of the prophylactic role of aspirin and/or clopidogrel on experimentally induced acute myocardial infarction in hypercholesterolemic rats.
    Drugs in R&D, 2014, Volume: 14, Issue:4

    Topics: Animals; Aspirin; C-Reactive Protein; Cholesterol; Clopidogrel; Creatine Kinase; Diet, High-Fat; Dru

2014
[Does acetylsalicylic acid and vitamin K antagonists are risk factors of macular degeneration related with age?].
    Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, 2015, Volume: 38, Issue:225

    Topics: Acenocoumarol; Aged; Anticoagulants; Aspirin; Case-Control Studies; Causality; Comorbidity; Female;

2015
Trends in myocardial infarction secondary prevention: The National Health and Nutrition Examination Surveys (NHANES), 1999-2012.
    Journal of the American Heart Association, 2015, Apr-22, Volume: 4, Issue:4

    Topics: Aged; Aspirin; Blood Glucose; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperc

2015
Association Between Statin Use and Endometrial Cancer Survival.
    Obstetrics and gynecology, 2015, Volume: 126, Issue:1

    Topics: Adult; Aged; Aspirin; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Hydroxymethylglutary

2015
Aspirin Use for the Primary Prevention of Myocardial Infarction Among Men in North Carolina, 2013.
    Preventing chronic disease, 2015, Nov-19, Volume: 12

    Topics: Aged; Aspirin; Behavioral Risk Factor Surveillance System; Diabetes Mellitus; Humans; Hypercholester

2015
Study of oxidative and inflammatory parameters in LDLr-KO mice treated with a hypercholesterolemic diet: Comparison between the use of Campomanesia xanthocarpa and acetylsalicylic acid.
    Phytomedicine : international journal of phytotherapy and phytopharmacology, 2016, Oct-15, Volume: 23, Issue:11

    Topics: Animals; Aspirin; Atherosclerosis; Brazil; Hypercholesterolemia; Inflammation; Lipoproteins, LDL; Ma

2016
[An atypical presentation of celiac disease: central retinal vein occlusion].
    The Pan African medical journal, 2015, Volume: 22

    Topics: Adult; Anemia, Iron-Deficiency; Aspirin; Biopsy; Celiac Disease; Diet, Gluten-Free; Female; Humans;

2015
Association of Low-Dose Aspirin and Survival of Women With Endometrial Cancer.
    Obstetrics and gynecology, 2016, Volume: 128, Issue:1

    Topics: Adenocarcinoma; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Comorbidity; Diabetes Mellit

2016
Antioxidative action of aspirin on endothelial function in hypercholesterolaemic rats.
    Basic & clinical pharmacology & toxicology, 2008, Volume: 103, Issue:4

    Topics: Animals; Antioxidants; Aorta, Thoracic; Aspirin; Cholesterol; Disease Models, Animal; Endothelium, V

2008
Antiatherosclerotic activity of ibuprofen, a non-selective COX inhibitor--an animal study.
    Indian journal of experimental biology, 2008, Volume: 46, Issue:6

    Topics: Animals; Anti-Inflammatory Agents; Antiparasitic Agents; Aspirin; Atherosclerosis; Celecoxib; Diseas

2008
Using icon arrays to communicate medical risks: overcoming low numeracy.
    Health psychology : official journal of the Division of Health Psychology, American Psychological Association, 2009, Volume: 28, Issue:2

    Topics: Adult; Aged; Anticholesteremic Agents; Arteriosclerosis; Aspirin; Attitude to Health; Computer Graph

2009
Comparison of LDL cholesterol concentrations by Friedewald calculation and direct measurement in relation to cardiovascular events in 27,331 women.
    Clinical chemistry, 2009, Volume: 55, Issue:5

    Topics: Aspirin; Cardiovascular Diseases; Cholesterol, LDL; Cohort Studies; Fasting; Female; Humans; Hyperch

2009
Dietary, lifestyle, and clinical predictors of lipoprotein-associated phospholipase A2 activity in individuals without coronary artery disease.
    The American journal of clinical nutrition, 2010, Volume: 91, Issue:3

    Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Adult; Age Factors; Aged; Alcohol Drinking; Antichol

2010
The effect of aspirin on atherogenic diet-induced diabetes mellitus.
    Basic & clinical pharmacology & toxicology, 2011, Volume: 108, Issue:6

    Topics: Adipose Tissue; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Glucose; Cholestero

2011
Fabry disease and Factor V Leiden: a potent vascular risk combination.
    Internal medicine journal, 2011, Volume: 41, Issue:5

    Topics: Activated Protein C Resistance; alpha-Galactosidase; Aspirin; Atorvastatin; Coronary Stenosis; Defib

2011
Ischemic stroke in patients receiving aspirin.
    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2012, Volume: 21, Issue:8

    Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Argentina; Aspirin; Brain Ischemia; Chi-Square Dis

2012
Chronic treatment with nitric oxide-releasing aspirin reduces plasma low-density lipoprotein oxidation and oxidative stress, arterial oxidation-specific epitopes, and atherogenesis in hypercholesterolemic mice.
    Proceedings of the National Academy of Sciences of the United States of America, 2002, Sep-17, Volume: 99, Issue:19

    Topics: Animals; Aorta, Thoracic; Arteriosclerosis; Aspirin; Foam Cells; Hypercholesterolemia; Lipoproteins,

2002
Reasons for resistance to aspirin in cardiovascular disease.
    Circulation, 2002, Nov-26, Volume: 106, Issue:22

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Coagulation; Cardiovascular Diseases; Cycloo

2002
Prior aspirin use in unstable angina patients with modified plasma inflammatory markers and endothelial nitric oxide synthase in neutrophils.
    European journal of clinical investigation, 2002, Volume: 32, Issue:12

    Topics: Aged; Angina, Unstable; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Biomarkers; Case-Control S

2002
Suppression of oxidative stress as a mechanism of reduction of hypercholesterolemic atherosclerosis by aspirin.
    Journal of cardiovascular pharmacology and therapeutics, 2003, Volume: 8, Issue:1

    Topics: Animals; Aorta; Aspirin; Cholesterol; Cholesterol, Dietary; Coronary Artery Disease; Cyclooxygenase

2003
Smoking and the risk of hemorrhagic stroke in men.
    Stroke, 2003, Volume: 34, Issue:5

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Alcohol Drinking; Aspirin; beta Carotene; Body Mass Ind

2003
Management and short-term outcome of diabetic patients hospitalized for acute myocardial infarction: results of a nationwide French survey.
    Diabetes & metabolism, 2003, Volume: 29, Issue:3

    Topics: Adrenergic beta-Antagonists; Aged; Aspirin; Body Mass Index; Diabetic Angiopathies; Female; France;

2003
Does cardiovascular therapy affect the onset and recurrence of preretinal and vitreous haemorrhage in diabetic eye disease?
    Eye (London, England), 2004, Volume: 18, Issue:8

    Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiovascular Agents; Cardiovascula

2004
Soluble CD40 ligand, soluble P-selectin, interleukin-6, and tissue factor in diabetes mellitus: relationships to cardiovascular disease and risk factor intervention.
    Circulation, 2004, Jun-01, Volume: 109, Issue:21

    Topics: Aged; Aspirin; Biomarkers; Blood Coagulation; Cardiovascular Diseases; CD40 Ligand; Cohort Studies;

2004
Cardiovascular disease risk reduction in the Behavioral Risk Factor Surveillance System.
    American journal of preventive medicine, 2004, Volume: 27, Issue:1

    Topics: Aspirin; Cardiovascular Diseases; Cross-Sectional Studies; Exercise; Feeding Behavior; Female; Healt

2004
More on: aspirin resistance.
    Journal of thrombosis and haemostasis : JTH, 2004, Volume: 2, Issue:8

    Topics: Alleles; Aspirin; Drug Resistance; Factor XIII; Fibrinolytic Agents; Genotype; Humans; Hypercholeste

2004
Explaining the increase in coronary heart disease mortality in Beijing between 1984 and 1999.
    Circulation, 2004, Sep-07, Volume: 110, Issue:10

    Topics: Adult; Aged; Antihypertensive Agents; Aspirin; Cardiovascular Agents; China; Coronary Disease; Devel

2004
Predictors of cognitive dysfunction in patients with systemic lupus erythematosus.
    Neurology, 2005, Jan-25, Volume: 64, Issue:2

    Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Antiphospholipid; Aspirin; Autoant

2005
A case of acute pancreatitis possibly associated with combined salicylate and simvastatin treatment.
    JOP : Journal of the pancreas, 2005, May-10, Volume: 6, Issue:3

    Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Aspirin; Cholangio

2005
[Highlights from the American College of Cardiology Annual Scientific Session 2005: March 5-9, 2005, Orlando, Florida].
    Revue medicale suisse, 2005, May-04, Volume: 1, Issue:18

    Topics: Aspirin; Cardiovascular Diseases; Cholesterol, LDL; Clopidogrel; Humans; Hypercholesterolemia; Obesi

2005
Association between body mass index and CKD in apparently healthy men.
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 2005, Volume: 46, Issue:5

    Topics: Adult; Aspirin; beta Carotene; Body Mass Index; Cardiovascular Diseases; Chronic Disease; Cohort Stu

2005
Progress of leukoaraiosis is inhibited by correction of platelet hyper-aggregability.
    International psychogeriatrics, 2005, Volume: 17, Issue:4

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Aspirin; Brain; Dementia, Va

2005
[Delayed coronary heart disease diagnosis, incomplete therapy. Misunderstood women's hearts].
    MMW Fortschritte der Medizin, 2005, Dec-01, Volume: 147, Issue:48

    Topics: Aspirin; Cholesterol, LDL; Coronary Disease; Diagnosis, Differential; Female; Humans; Hypercholester

2005
[Recording of risk factors and preventive pharmaceutical therapy among ischemic heart disease patients in family practice during the years 1993-1998].
    Harefuah, 2006, Volume: 145, Issue:4

    Topics: Adrenergic beta-Antagonists; Aspirin; Blood Pressure; Cholesterol; Cohort Studies; Family Practice;

2006
Secondary prevention of coronary heart disease in primary health care.
    Bosnian journal of basic medical sciences, 2006, Volume: 6, Issue:2

    Topics: Adult; Aged; Aspirin; Body Mass Index; Coronary Disease; Female; Humans; Hypercholesterolemia; Hyper

2006
Swine model of carotid artery atherosclerosis: experimental induction by surgical partial ligation and dietary hypercholesterolemia.
    AJNR. American journal of neuroradiology, 2006, Volume: 27, Issue:9

    Topics: Angiography; Angioplasty, Balloon; Animals; Aspirin; Calcinosis; Carotid Arteries; Carotid Artery In

2006
Validation studies of the health improvement network (THIN) database for pharmacoepidemiology research.
    Pharmacoepidemiology and drug safety, 2007, Volume: 16, Issue:4

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Control Studies; Colonic Neoplasms; Databases

2007
Aspirin restores normal baroreflex function in hypercholesterolemic rats by its antioxidative action.
    European journal of pharmacology, 2007, Feb-05, Volume: 556, Issue:1-3

    Topics: Animals; Antioxidants; Aspirin; Baroreflex; Blood Pressure; Cholesterol; Cholesterol, Dietary; Heart

2007
Cholesterol, cholesterol-lowering agents/statins, and urologic disease: Part V--Statins versus aspirin for primary prevention, and the winner is...?
    Urologic nursing, 2007, Volume: 27, Issue:2

    Topics: Aspirin; Cardiovascular Diseases; Cause of Death; Drug Costs; Evidence-Based Medicine; Humans; Hydro

2007
Effect of statin drugs and aspirin on open-angle glaucoma progression.
    Clinical & experimental ophthalmology, 2007, Volume: 35, Issue:6

    Topics: Aspirin; Disease Progression; Drug Therapy, Combination; Glaucoma, Open-Angle; Humans; Hydroxymethyl

2007
Roles of platelet and endothelial cell COX-1 in hypercholesterolemia-induced microvascular dysfunction.
    American journal of physiology. Heart and circulatory physiology, 2007, Volume: 293, Issue:6

    Topics: Animals; Aspirin; Blood Platelets; Bone Marrow Transplantation; Cardiovascular Diseases; Cell Adhesi

2007
[Beneficial effects of statins and angiotensin converting enzyme inhibitors on aggregability of red blood cells in hypertensive patients].
    Folia medica Cracoviensia, 2006, Volume: 47, Issue:1-4

    Topics: Adolescent; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Aspirin;

2006
[Prescription patterns for antilipidemic drugs in a group of Colombian patients].
    Revista panamericana de salud publica = Pan American journal of public health, 2008, Volume: 23, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antihypertensive Agents

2008
Secondary prevention of coronary heart disease.
    Acta cardiologica, 1984, Volume: 39, Issue:4

    Topics: Adrenergic beta-Antagonists; Anticoagulants; Aspirin; Coronary Disease; Diabetes Mellitus; Feeding B

1984
Circulating platelets plasma-membrane of normocholesterolemic and hypercholesterolemic rabbits tested with aspirin: a freeze etching study of the platelet plasma-membrane "protuberances".
    Pharmacological research communications, 1980, Volume: 12, Issue:1

    Topics: Animals; Aspirin; Blood Platelets; Cell Membrane; Cytoplasm; Diet; Freeze Etching; Hypercholesterole

1980
Epidemiological feasibility of cardiovascular primary prevention in general practice: a trial of vitamin E and aspirin. Collaborative group of the Primary Prevention Project.
    Journal of cardiovascular risk, 1995, Volume: 2, Issue:2

    Topics: Aged; Arteriosclerosis; Aspirin; Cardiovascular Diseases; Clinical Protocols; Contraindications; Dia

1995
Inhibitory effects of aspirin on coronary hyperreactivity to autacoids after arterial balloon injury in miniature pigs.
    Journal of cardiovascular pharmacology, 1995, Volume: 25, Issue:2

    Topics: Angiography; Angioplasty, Balloon, Coronary; Animals; Aspirin; Autacoids; Blood Pressure; Constricti

1995
Risk factors for carotid atherosclerosis and platelet activation.
    Japanese circulation journal, 1994, Volume: 58, Issue:6

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Arteriosclerosis; Aspirin; Carotid Artery Diseases; Fem

1994
Recent developments in secondary prevention of stroke.
    Scottish medical journal, 1993, Volume: 38, Issue:3 Suppl

    Topics: Aspirin; Cerebrovascular Disorders; Endarterectomy, Carotid; Humans; Hypercholesterolemia; Myocardia

1993
Inhibitory effects of heparin, aspirin and ketanserin on coronary artery vasoconstriction after arterial balloon injury in hypercholesterolemic miniature pigs.
    Journal of the American College of Cardiology, 1993, Volume: 22, Issue:1

    Topics: Angioplasty, Balloon, Coronary; Animals; Aspirin; Blood Platelets; Coronary Vessels; Drug Interactio

1993
Low-dose aspirin does not attenuate platelet aggregation or atherosclerosis in miniature swine but decreases production of aortic wall prostacyclin.
    Prostaglandins, leukotrienes, and essential fatty acids, 1995, Volume: 53, Issue:5

    Topics: 6-Ketoprostaglandin F1 alpha; Animals; Aorta; Arteriosclerosis; Aspirin; Azo Compounds; Coloring Age

1995
Inhibition of thrombin generation by aspirin is blunted in hypercholesterolemia.
    Arteriosclerosis, thrombosis, and vascular biology, 1996, Volume: 16, Issue:8

    Topics: Adult; Aged; Angina Pectoris; Antithrombins; Aspirin; Cholesterol; Female; Humans; Hypercholesterole

1996
[Should individuals without evidence of coronary disease and with risk factors receive continuous treatment with aspirin? Arguments in favor].
    Revista espanola de cardiologia, 1996, Volume: 49, Issue:11

    Topics: Age Factors; Aspirin; Cost-Benefit Analysis; Diabetes Complications; Female; Humans; Hypercholestero

1996
Mobile thromboses of the aortic arch without aortic debris. A transesophageal echocardiographic finding associated with unexplained arterial embolism. The Filiale Echocardiographie de la Société Française de Cardiologie.
    Circulation, 1997, Jul-01, Volume: 96, Issue:1

    Topics: Adult; Aorta, Thoracic; Arteriosclerosis; Aspirin; Blood Coagulation Tests; Diabetes Complications;

1997
Both dietary fish-oil supplementation and aspirin fail to inhibit atherosclerosis in long-term vein bypass grafts in moderately hypercholesterolemic nonhuman primates.
    Circulation, 1997, Aug-05, Volume: 96, Issue:3

    Topics: Animals; Arteriosclerosis; Aspirin; Coronary Artery Bypass; Dietary Fats, Unsaturated; Drug Synergis

1997
In vivo formation of 8-Epi-prostaglandin F2 alpha is increased in hypercholesterolemia.
    Arteriosclerosis, thrombosis, and vascular biology, 1997, Volume: 17, Issue:11

    Topics: Antioxidants; Aspirin; Cardiovascular Diseases; Cross-Sectional Studies; Cyclooxygenase Inhibitors;

1997
Secondary prevention in coronary heart disease: baseline survey of provision in general practice.
    BMJ (Clinical research ed.), 1998, May-09, Volume: 316, Issue:7142

    Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Blood P

1998
[Heart magnyl or statins?].
    Ugeskrift for laeger, 1998, Dec-14, Volume: 160, Issue:51

    Topics: Anticholesteremic Agents; Aspirin; Coronary Disease; Humans; Hypercholesterolemia; Risk Factors

1998
Management of ischaemic heart disease in primary care: towards better practice. STaRNet. South Thames Region Network.
    Journal of public health medicine, 1999, Volume: 21, Issue:2

    Topics: Adult; Aged; Anticholesteremic Agents; Aspirin; Body Mass Index; Cross-Sectional Studies; England; H

1999
Effect of low-dose aspirin on the markers of oxidative stress.
    Cardiovascular drugs and therapy, 1999, Volume: 13, Issue:6

    Topics: Adult; Antioxidants; Aspirin; Biomarkers; Dose-Response Relationship, Drug; Humans; Hypercholesterol

1999
Antiplatelet and antithrombotic effects of orbofiban, a new orally active GPIIb/IIIa antagonist, in guinea pigs.
    Thrombosis research, 2000, Mar-01, Volume: 97, Issue:5

    Topics: Adenosine Diphosphate; Administration, Oral; Alanine; Animals; Arteriovenous Shunt, Surgical; Aspiri

2000
Involvement of cyclooxygenase 2 in the protective effect of 17beta-estradiol on hypercholesterolemic rabbit aorta.
    Biochemical and biophysical research communications, 2000, Aug-28, Volume: 275, Issue:2

    Topics: Acetylcholine; Adenine; Animals; Aorta; Aspirin; Cholesterol; Cyclooxygenase 2; Cyclooxygenase 2 Inh

2000
Anti-inflammatory effects of simvastatin in subjects with hypercholesterolemia.
    International journal of cardiology, 2001, Volume: 77, Issue:2-3

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Aspirin; C-Reactive Protei

2001
Effects of nitric oxide-releasing aspirin versus aspirin on restenosis in hypercholesterolemic mice.
    Proceedings of the National Academy of Sciences of the United States of America, 2001, Feb-27, Volume: 98, Issue:5

    Topics: Animals; Aspirin; Constriction, Pathologic; Hypercholesterolemia; Mice; Mice, Inbred C57BL; Mice, Kn

2001
[Antibodies to phospholipids and ischemic disorders of cerebral circulation in young age].
    Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 1997, Volume: 97, Issue:6

    Topics: Adolescent; Adult; Age Factors; Alcohol Drinking; Antibodies, Antiphospholipid; Anticoagulants; Anti

1997
Increased platelet glycoprotein V levels in patients with coronary and peripheral atherosclerosis--the influence of aspirin and cigarette smoking.
    Thrombosis and haemostasis, 2001, Volume: 86, Issue:3

    Topics: Adenosine Diphosphate; Adult; Aged; Arteriosclerosis; Aspirin; beta-Thromboglobulin; Biomarkers; Cho

2001
Platelet inhibition reduces cyclic flow variations and neointimal proliferation in normal and hypercholesterolemic-atherosclerotic canine coronary arteries.
    Circulation, 2001, Nov-06, Volume: 104, Issue:19

    Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Animals; Aspirin; Blood Coagulation; Blood Flo

2001
Optimizing drug therapy in patients with cardiovascular disease: the impact of pharmacist-managed pharmacotherapy clinics in a primary care setting.
    Pharmacotherapy, 2002, Volume: 22, Issue:6

    Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiovascular Agents; Cardiovascular Disea

2002
Anti-platelet drugs and portacaval anastomosis for homozygous hypercholesterolaemia.
    Lancet (London, England), 1976, Dec-25, Volume: 2, Issue:8000

    Topics: Adolescent; Adult; Aspirin; Child; Dipyridamole; Female; Homozygote; Humans; Hypercholesterolemia; M

1976
Concomitant aspirin treatment abolishes the antiatherosclerotic effects of the calcium channel blocker isradipine mediated by PGI2.
    Agents and actions. Supplements, 1992, Volume: 37

    Topics: Animals; Aorta, Abdominal; Arteriosclerosis; Aspirin; Calcium Channel Blockers; Cholesterol; Dihydro

1992
Increased thromboxane biosynthesis in type IIa hypercholesterolemia.
    Circulation, 1992, Volume: 85, Issue:5

    Topics: Adult; Aged; Anticholesteremic Agents; Aspirin; Blood Platelets; Dose-Response Relationship, Drug; F

1992
[Cardiovascular risk factors and restenosis after PTCA].
    Zeitschrift fur Kardiologie, 1992, Volume: 81, Issue:3

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Combined Modality Therapy; Coronary Angiography; Coro

1992
Platelet hypersensitivity in cholesterol-fed rabbits: enhancement of thromboxane A2-dependent and thrombin-induced, thromboxane A2-independent platelet responses.
    Atherosclerosis, 1991, Volume: 88, Issue:1

    Topics: Adenosine Diphosphate; Animals; Aspirin; Blood Platelets; Cholesterol; Collagen; Hypercholesterolemi

1991
Impaired vasodilation of forearm resistance vessels in hypercholesterolemic humans.
    The Journal of clinical investigation, 1990, Volume: 86, Issue:1

    Topics: Adult; Arm; Aspirin; Female; Humans; Hypercholesterolemia; Male; Methacholine Chloride; Methacholine

1990
Thrombin-induced inositol phosphate production by platelets from rats with diet-induced or genetically determined hypercholesterolemia.
    The Journal of laboratory and clinical medicine, 1990, Volume: 115, Issue:2

    Topics: Animals; Aspirin; Blood Platelets; Cholesterol, Dietary; Creatine Kinase; Hypercholesterolemia; Inos

1990
Managing lipid disorders.
    Iowa medicine : journal of the Iowa Medical Society, 1990, Volume: 80, Issue:4

    Topics: Aspirin; Delayed-Action Preparations; Drug Therapy, Combination; Humans; Hypercholesterolemia; Niaci

1990
Myocardial infarction. Primary prevention.
    The Practitioner, 1990, Feb-22, Volume: 234, Issue:1483

    Topics: Adult; Aspirin; Female; Humans; Hypercholesterolemia; Hypertension; Male; Middle Aged; Myocardial In

1990
Mechanisms responsible for inhibition of vein-graft arteriosclerosis by fish oil.
    Circulation, 1989, Volume: 80, Issue:3 Pt 1

    Topics: Animals; Arteriosclerosis; Aspirin; Carotid Arteries; Dogs; Drug Evaluation, Preclinical; Drug Thera

1989
Blood lipid peroxides in TIA: relation to platelet function and metabolic profile.
    Acta neurologica Scandinavica, 1989, Volume: 80, Issue:4

    Topics: Administration, Oral; Aged; Arteriosclerosis; Aspirin; Blood Glucose; Blood Platelets; Coronary Dise

1989
Differential effect of platelet inhibitors in normal and in hypercholesterolaemic subjects.
    British journal of clinical pharmacology, 1985, Volume: 19, Issue:6

    Topics: Adult; Aspirin; Cyclic AMP; Dipyridamole; Epoprostenol; Humans; Hypercholesterolemia; In Vitro Techn

1985
Prolongation of platelet survival in hypercholesterolaemic rabbits by CGS 12970 (3-methyl-2-(3-pyridyl)-1 indoleoctanoic acid) and dazoxiben.
    Thrombosis research, 1987, Mar-15, Volume: 45, Issue:6

    Topics: Animals; Aspirin; Blood Platelets; Cell Survival; Cholesterol, Dietary; Cyclooxygenase Inhibitors; H

1987
[Current data on the physiopathological and therapeutic importance of vitamin C].
    Giornale di clinica medica, 1974, Volume: 55, Issue:1

    Topics: Ascorbic Acid; Ascorbic Acid Deficiency; Aspirin; Barbiturates; Common Cold; Humans; Hypercholestero

1974